Milestone Pharmaceuticals Inc.
MISTNASDAQHealthcareBiotechnology
Previous close
$1.055
+$0.025 · +2.43%
MIST company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
37
Expensive
Momentum
19
Strong Down
Sentiment
31
Bearish
Risk resilience
37
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteMilestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- CA
- CEO
- Joseph G. Oliveto
- Listed since
- May 9, 2019
- Employees
- 38
Market position
Day range
Current $1.055
52-week range
Current $1.055
- Open
- $1.07
- Previous close
- $1.03
- Volume
- 1.92M
- 1.31× average
- Average volume
- 1.47M
- Average daily volume
- Market cap
- 131.35M USD
- Beta
- 0.98
- Market reference 1
- 50-day average
- $1.2116
- -12.93% below average
- 200-day average
- $1.6999
- -37.94% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 154.77M USD
- P/E (TTM)
- -1.53×
- P/B (TTM)
- 8.03×
- P/S (TTM)
- 56.06×
- EV / EBITDA
- -2.6×
- Earnings yield
- -37.21%
- Free cash flow yield
- -29.12%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 94.58%
- Operating margin
- -3353.01%
- Net margin
- -3585.62%
- Return on equity
- -150.97%
- Return on assets
- -55.53%
- Return on invested capital
- -62.00%
Financial health
- Debt / equity
- 3.3×
- Current ratio
- 8.01×
Earnings
- EPS beat rate
- 45%
- 5 beats, 6 misses, 0 met estimates
- Average EPS surprise
- -40.91%
- 11 comparable reports
- Latest EPS result
- -0.21
- Estimate -0.2 · Miss by 7.69%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$4.50
326.54% upsideRating distribution
7 ratingsMIST peers
ETFs holding MIST
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research MISTresearch.disclaimer